| P2093 | author name string | Naoki Kashihara | |
| | Minoru Satoh | |
| | Naruya Tomita | |
| | Hajime Nagasu | |
| | Sohachi Fujimoto | |
| | Tamaki Sasaki | |
| P2860 | cites work | Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease | Q80482373 |
| | Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure | Q80495998 |
| | Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis | Q81039929 |
| | Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats | Q83279212 |
| | Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension | Q28321081 |
| | Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). | Q31437386 |
| | Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats | Q33492060 |
| | Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group | Q34025761 |
| | Sympathetic nervous system function in renal hypertension | Q34633353 |
| | Guidelines for antihypertensive treatment: an update after the ALLHAT study | Q35611122 |
| | Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment | Q35746837 |
| | Beta blockers in the management of chronic kidney disease | Q36614867 |
| | Ca2+ channel subtypes and pharmacology in the kidney | Q36739124 |
| | Cardiovascular neural regulation explored in the frequency domain | Q37207416 |
| | Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt-sensitive rats | Q43124691 |
| | Selenium-deficient diet induces renal oxidative stress and injury via TGF-beta1 in normal and diabetic rats | Q43548892 |
| | Enhanced sympathoexcitatory and pressor responses to central Na+ in Dahl salt-sensitive vs. -resistant rats | Q43773104 |
| | Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo | Q43777442 |
| | Clinical efficacy of efonidipine hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities | Q44291302 |
| | Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties | Q44835411 |
| | Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes | Q45028923 |
| | Cilnidipine inhibits the sympathetic nerve activity and improves baroreflex sensitivity in patients with hypertension. | Q46039860 |
| | Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats | Q46213560 |
| | Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients | Q46217490 |
| | Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet | Q46479704 |
| | Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity | Q46663990 |
| | Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production | Q46687591 |
| | Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats | Q46975675 |
| | Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in salt-sensitive hypertension | Q48132384 |
| | Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats | Q48529292 |
| | Impaired myogenic responsiveness of renal microvessels in Dahl salt-sensitive rats | Q54264660 |
| | Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension. | Q54284700 |
| | Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog | Q56864410 |
| | Heart rate variability: Standards of measurement, physiological interpretation, and clinical use | Q57309208 |
| | Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity | Q61684184 |
| | Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms | Q70673075 |
| | Optimisation of antihypertensive treatment by crossover rotation of four major classes | Q77904788 |
| | Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis | Q80224070 |
| P433 | issue | 3 | |
| P921 | main subject | azelnidipine | Q4832365 |
| P304 | page(s) | 348-355 | |
| P577 | publication date | 2011-11-10 | |
| P1433 | published in | Hypertension Research | Q15762136 |
| P1476 | title | Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity | |
| P478 | volume | 35 | |